The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment of patients with chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström macroglobulinemia, significantly improving clinical outcomes. However, IB therapy has been associated with an increased risk of atrial fibrillation (AF) and bleeding. We report on the expert opinion that a group of Italian haematologists, cardiologists, and pharmacologists jointly released to improve the practical management of patients at risk for AF and bleeding during treatment with IB. A proper pretreatment assessment to identify patients who are at a higher risk, careful choice of concomitant drugs, regular monitoring, and multispecialist approach were characterized as the main principles of clinical management of these patients. For patients developing AF, anticoagulant and antiarrhythmic therapy must be guided by considerations about efficacy, safety, and risk of pharmacokinetic interactions with IB. For patients experiencing bleeding or requiring procedures that increase the risk of bleeding, considerations about platelet turnover, IB-related platelet dysfunctions, and bleeding worsening by concomitant anticoagulants or antiplatelet agents provide clues to manage bleeding. Overall, AF and bleeding are manageable clinical events in patients receiving IB, not requiring drug interruption in most cases. Preexisting AF should not represent an absolute contraindication to IB therapy. For each patient candidate for IB, strategies of risk assessment and mitigation may allow to exploit the life-saving effects of in chronic lymphocytic leukaemia and mantle cell lymphoma.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding / Boriani, Giuseppe; Corradini, Paolo; Cuneo, Antonio; Falanga, Anna; Foà, Robin; Gaidano, Gianluca; Ghia, Paolo Prospero; Martelli, Maurizio; Marasca, Roberto; Massaia, Massimo; Mauro, Francesca Romana; Minotti, Giorgio; Molica, Stefano; Montillo, Marco; Pinto, Antonio; Tedeschi, Alessandra; Vitolo, Umberto; Zinzani, Pier Luigi. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - 36:4(2018), pp. 624-632. [10.1002/hon.2503]

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding

Boriani, Giuseppe;Cuneo, Antonio;Marasca, Roberto;
2018

Abstract

The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment of patients with chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström macroglobulinemia, significantly improving clinical outcomes. However, IB therapy has been associated with an increased risk of atrial fibrillation (AF) and bleeding. We report on the expert opinion that a group of Italian haematologists, cardiologists, and pharmacologists jointly released to improve the practical management of patients at risk for AF and bleeding during treatment with IB. A proper pretreatment assessment to identify patients who are at a higher risk, careful choice of concomitant drugs, regular monitoring, and multispecialist approach were characterized as the main principles of clinical management of these patients. For patients developing AF, anticoagulant and antiarrhythmic therapy must be guided by considerations about efficacy, safety, and risk of pharmacokinetic interactions with IB. For patients experiencing bleeding or requiring procedures that increase the risk of bleeding, considerations about platelet turnover, IB-related platelet dysfunctions, and bleeding worsening by concomitant anticoagulants or antiplatelet agents provide clues to manage bleeding. Overall, AF and bleeding are manageable clinical events in patients receiving IB, not requiring drug interruption in most cases. Preexisting AF should not represent an absolute contraindication to IB therapy. For each patient candidate for IB, strategies of risk assessment and mitigation may allow to exploit the life-saving effects of in chronic lymphocytic leukaemia and mantle cell lymphoma.
7-mar-2018
36
4
624
632
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding / Boriani, Giuseppe; Corradini, Paolo; Cuneo, Antonio; Falanga, Anna; Foà, Robin; Gaidano, Gianluca; Ghia, Paolo Prospero; Martelli, Maurizio; Marasca, Roberto; Massaia, Massimo; Mauro, Francesca Romana; Minotti, Giorgio; Molica, Stefano; Montillo, Marco; Pinto, Antonio; Tedeschi, Alessandra; Vitolo, Umberto; Zinzani, Pier Luigi. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - 36:4(2018), pp. 624-632. [10.1002/hon.2503]
Boriani, Giuseppe; Corradini, Paolo; Cuneo, Antonio; Falanga, Anna; Foà, Robin; Gaidano, Gianluca; Ghia, Paolo Prospero; Martelli, Maurizio; Marasca, Roberto; Massaia, Massimo; Mauro, Francesca Romana; Minotti, Giorgio; Molica, Stefano; Montillo, Marco; Pinto, Antonio; Tedeschi, Alessandra; Vitolo, Umberto; Zinzani, Pier Luigi
File in questo prodotto:
File Dimensione Formato  
hon.2503.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 589.81 kB
Formato Adobe PDF
589.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1167956
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 39
social impact